Page last updated: 2024-09-04

atazanavir sulfate and raltegravir potassium

atazanavir sulfate has been researched along with raltegravir potassium in 48 studies

Compound Research Comparison

Studies (atazanavir sulfate)	Trials (atazanavir sulfate)	Recent Studies (post-2010) (atazanavir sulfate)	Studies (raltegravir potassium)	Trials (raltegravir potassium)	Recent Studies (post-2010) (raltegravir potassium)
1,102	246	590	1,238	243	879

Protein Interaction Comparison

Protein	Taxonomy	atazanavir sulfate (IC50)	raltegravir potassium (IC50)
Translocator protein	Rattus norvegicus (Norway rat)		0.13
Integrase	Human immunodeficiency virus 1		0.0494

Research

Studies (48)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (12.50)	29.6817
2010's	36 (75.00)	24.3611
2020's	6 (12.50)	2.80

Authors

Authors	Studies
Sax, PE	1
Chen, J; Gatell, JM; Gonzalez, CJ; Grinsztejn, B; Harvey, CM; Isaacs, RD; Katlama, C; Lazzarin, A; Nguyen, BY; Vittecoq, D	1
Azrolan, N; Breidinger, S; Bridson, WE; Ghosh, K; Gottesdiener, KM; Gutierrez, MJ; Iwamoto, M; Liou, SY; Mistry, GC; Petry, AS; Stone, JA; Wagner, JA; Wenning, LA	1
Fenstersheib, M; Fleischbein, E; Martelino, R; O'Brien, J	1
Boyle, BA; Cohen, CJ; DeJesus, E; Elion, R; Frank, I; Moyle, GJ; Sax, PE	1
Sankawa, Y	1
Ando, H; Minami, R; Miyamura, T; Suematsu, E; Takahama, S; Yamamoto, M	1
Calmy, A; Decosterd, L; di Iulio, J; Fayet, A; Jelliffe, R; Kanani, M; Lee, JS; Margol, A; Neely, M; von Schoen-Angerer, T	1
Baldelli, S; Cattaneo, D; Clementi, E; Conti, F; Cozzi, V; Ripamonti, D	1
Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M	1
Amin, J; Cooper, DA; Cordery, DV; Hesse, K	1
Bertz, R; Breidinger, S; Butterton, J; Comisar, W; Panebianco, D; Persson, A; Stonier, M; Zhang, J; Zhu, L	1
Burger, DM; Hamers, RL; van den Berk, GE; Welzen, ME	1
Andrade-Villanueva, J; Cheng, AK; Chuck, SL; Clotet, B; Clumeck, N; Lamarca, A; Liu, YP; Margot, N; Molina, JM; Zhong, L	1
Baldelli, S; Cattaneo, D; Clementi, E; Cozzi, V; Fucile, S; Ripamonti, D	1
de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ	1
Bower, M; Dunning, J; Manley, K; Nelson, M	1
Back, DJ; Baietto, L; Bonora, S; Calcagno, A; Cuenca, L; Di Perri, G; DʼAvolio, A; Moss, D; Owen, A; Rodriguez-Novoa, S; Siccardi, M; Simiele, M; Soriano, V	1
Beileiter, K; Bloch, M; Boyd, MA; Carey, D; Cooper, DA; Emery, S; MacRae, K; Pett, SL; Ray, JE; Wand, H	1
Bonora, S; Calcagno, A; D'Avolio, A; Di Perri, G; Montrucchio, C; Simiele, M; Tettoni, MC; Trentini, L	1
Burger, DM; Colbers, EP; Jansen, A; Richter, C; Rockstroh, JK; van der Ven, AJ; van Luin, M; Wasmuth, JC	1
Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E	1
Guaraldi, G; Santoro, A; Stentarelli, C; Zona, S	1
Batard, ML; Bernard-Henry, C; Cheneau, C; De Mautort, E; Fafi-Kremer, S; Gantner, P; Koeppel, C; Muret, P; Partisani, M; Priester, M; Rey, D; Sueur, C	1
Bagella, P; Bonfanti, P; Carenzi, L; Celesia, BM; De Socio, GV; Dentone, C; Di Biagio, A; Franzetti, M; Libertone, R; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Parruti, G; Penco, G; Quirino, T; Ricci, E; Vichi, F	1
Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A	1
Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, R; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO	1
Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O	1
Anderson, PL; Caraway, P; Gardner, EM; Kerr, B; MaWhinney, S; Meditz, AL; Palmer, C; Predhomme, J; Searls, K; Seifert, S	1
Antinori, A; Baakili, A; Gatell, JM; Girard, PM; Klauck, I; Osiyemi, O; Pozniak, A; Serrano, O; Sevinsky, H; van Lunzen, J	1
Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X	1
Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G	1
Jones, R; Levy, JB; Milburn, J	1
Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO	1
Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO	1
Bethel-Brown, C; Brejda, J; Deschamps, K; East, L; Gartner, M; Krishna, R; Larson, P; Luk, JA; Manthos, H; Valiathan, C	1
Bonora, S; Bramato, C; Calcagno, A; Cenderello, G; D'Avolio, A; Di Perri, G; Marinaro, L; Orofino, G; Pirriatore, V; Ripamonti, D; Rizzi, M; Rusconi, S; Salassa, B; Trentini, L	1
Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A	1
Brogan, AJ; Davis, AE; Goodwin, B	1
El-Hage, N; Karuppan, MKM; Kashanchi, F; Lapierre, J; Ojha, CR; Pawitwar, S; Rodriguez, M	1
Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR	1
Biasiotto, G; Bonito, A; Calza, S; Castelli, F; Quiros-Roldan, E; Vezzoli, M; Zanella, I	1
Cottrell, ML; Deeks, SG; Hatano, H; Hoh, R; Hunt, PW; Kashuba, ADM; Lee, SA; Liegler, TJ; Savic, RM; Somsouk, M; Stephenson, S; Telwatte, S; Yukl, S	1
Avelino-Silva, VI; Fonseca, FF; Pascom, ARP; Pereira, G; Perini, FB; Pinho, RGG	1
Adrian, S; Beghetto, B; Erlandson, KM; Feng, H; Guaraldi, G; Lake, JE; Ligabue, G; Miao, H; Milic, J; Nardini, G; Roncaglia, E; Scherzinger, A	1
Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL	1
Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R	1

Reviews

4 review(s) available for atazanavir sulfate and raltegravir potassium

Article	Year
Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient. AIDS (London, England), 2008, Nov-12, Volume: 22, Issue:17 Topics: Alkaline Phosphatase; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium	2008
HIV-associated lipodystrophy: impact of antiretroviral therapy. Drugs, 2013, Volume: 73, Issue:13 Topics: Adiposity; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Nucleosides; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides	2013
Renal effects of novel antiretroviral drugs. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2017, 03-01, Volume: 32, Issue:3 Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir	2017
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review. The Pediatric infectious disease journal, 2017, Volume: 36, Issue:5 Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load	2017

Trials

17 trial(s) available for atazanavir sulfate and raltegravir potassium

Article	Year
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet (London, England), 2007, Apr-14, Volume: 369, Issue:9569 Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Oligopeptides; Organic Chemicals; Pyridines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Viral Load	2007
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2008, Jul-01, Volume: 47, Issue:1 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Double-Blind Method; Female; Humans; Male; Oligopeptides; Organic Chemicals; Placebos; Plasma; Pyridines; Pyrrolidinones; Raltegravir Potassium	2008
Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Adult; Atazanavir Sulfate; Drug Interactions; Female; HIV Integrase Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Young Adult	2010
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antiviral therapy, 2010, Volume: 15, Issue:8 Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Heart; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Time Factors; Young Adult	2010
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. The Lancet. Infectious diseases, 2012, Volume: 12, Issue:1 Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Atazanavir Sulfate; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load	2012
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor. British journal of clinical pharmacology, 2012, Volume: 74, Issue:2 Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir	2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults. Journal of acquired immune deficiency syndromes (1999), 2012, Jun-01, Volume: 60, Issue:2 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome	2012
Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients. HIV medicine, 2013, Volume: 14, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Viral Load; Young Adult	2013
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors]. MMW Fortschritte der Medizin, 2014, Jun-12, Volume: 156 Suppl 1 Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2014
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, 06-15, Volume: 60, Issue:12 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir	2015
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015, Aug-15, Volume: 61, Issue:4 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Darunavir; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Treatment Outcome	2015
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. The Journal of infectious diseases, 2015, Oct-15, Volume: 212, Issue:8 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult	2015
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study. Journal of acquired immune deficiency syndromes (1999), 2016, Apr-15, Volume: 71, Issue:5 Topics: Adult; Atazanavir Sulfate; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult	2016
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue. Journal of acquired immune deficiency syndromes (1999), 2016, 06-01, Volume: 72, Issue:2 Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome	2016
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antiviral therapy, 2017, Volume: 22, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir	2017
Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose. Biopharmaceutics & drug disposition, 2016, Volume: 37, Issue:9 Topics: Administration, Oral; Adult; Atazanavir Sulfate; Drug Interactions; Female; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Young Adult	2016
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States. PloS one, 2018, Volume: 13, Issue:8 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States	2018

Other Studies

27 other study(ies) available for atazanavir sulfate and raltegravir potassium

Article	Year
Meeting report. Report from ICAAC. AIDS clinical care, 2006, Volume: 18, Issue:12 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load	2006
Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use. The AIDS reader, 2009, Volume: 19, Issue:4 Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Dideoxynucleosides; Drug Interactions; HIV Infections; Humans; Interleukin-2; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium	2009
[Medication change due to side effects or possible long-term complications. Side effect management with vision]. MMW Fortschritte der Medizin, 2009, Apr-30, Volume: 151, Issue:18 Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Lopinavir; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic	2009
Comparison of the influence of four classes of HIV antiretrovirals on adipogenic differentiation: the minimal effect of raltegravir and atazanavir. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:2 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Anti-HIV Agents; Atazanavir Sulfate; Cell Differentiation; Gene Expression Regulation; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lipid Metabolism; Mice; Oligopeptides; Oxidative Stress; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors	2011
Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients. Therapeutic drug monitoring, 2010, Volume: 32, Issue:6 Topics: Adult; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium	2010
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report]. Medicina clinica, 2011, Sep-10, Volume: 137, Issue:6 Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine	2011
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antiviral therapy, 2010, Volume: 15, Issue:7 Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load	2010
Interaction between antiretroviral drugs and acenocoumarol. Antiviral therapy, 2011, Volume: 16, Issue:2 Topics: Acenocoumarol; Alkynes; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Venous Thrombosis	2011
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients. Fundamental & clinical pharmacology, 2013, Volume: 27, Issue:2 Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Biological Availability; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Young Adult	2013
HIV-associated gastric natural killer/T-cell lymphoma. International journal of STD & AIDS, 2012, Volume: 23, Issue:1 Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Atazanavir Sulfate; Cyclophosphamide; Doxorubicin; Female; HIV Seropositivity; Humans; Lamivudine; Lymphoma, Extranodal NK-T-Cell; Oligopeptides; Prednisone; Pyridines; Pyrrolidinones; Raltegravir Potassium; Stomach Neoplasms; Vincristine	2012
Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. Therapeutic drug monitoring, 2012, Volume: 34, Issue:2 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Gene Expression Regulation, Enzymologic; Genetic Variation; Genotype; Glucuronosyltransferase; HIV Integrase Inhibitors; Humans; Italy; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Spain	2012
Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:2 Topics: Anti-HIV Agents; Atazanavir Sulfate; Female; Humans; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir	2013
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. AIDS (London, England), 2013, Apr-24, Volume: 27, Issue:7 Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides	2013
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study. Scandinavian journal of infectious diseases, 2014, Volume: 46, Issue:12 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load	2014
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance. International journal of antimicrobial agents, 2015, Volume: 45, Issue:3 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Creatine Kinase; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Muscle Weakness; Myalgia; Oligopeptides; Prospective Studies; Pyridines; Pyrrolidinones; Raltegravir Potassium	2015
Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. AIDS research and human retroviruses, 2015, Volume: 31, Issue:10 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood; CD4 Lymphocyte Count; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Middle Aged; Raltegravir Potassium; T-Lymphocyte Subsets; Treatment Outcome; Viral Load	2015
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study. Medicine, 2016, Volume: 95, Issue:11 Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir	2016
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s. The Journal of infectious diseases, 2016, 09-01, Volume: 214, Issue:5 Topics: Adult; Anti-HIV Agents; Antigens, CD; Atazanavir Sulfate; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Male; Prospective Studies; Raltegravir Potassium; T-Lymphocyte Subsets	2016
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2017, Volume: 87 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Plasma; Raltegravir Potassium; Retrospective Studies; Selection, Genetic; Treatment Outcome; Viral Load	2017
Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes. Journal of neurovirology, 2019, Volume: 25, Issue:2 Topics: Acetyltransferases; Anti-HIV Agents; Astrocytes; Atazanavir Sulfate; Chromosomal Proteins, Non-Histone; Dideoxynucleosides; Drug Combinations; Emtricitabine; Gene Expression Regulation; Histone Deacetylases; HIV-1; Host-Pathogen Interactions; Humans; Lopinavir; Lysosomes; Membrane Proteins; Mitochondria; Morphine; Narcotics; Nuclear Proteins; Primary Cell Culture; Protein-Arginine N-Methyltransferases; Raltegravir Potassium; Ritonavir; Sequestosome-1 Protein; Signal Transduction; Trans-Activators; Virus Replication	2019
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs. Antimicrobial agents and chemotherapy, 2019, 12-20, Volume: 64, Issue:1 Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Emtricitabine; Female; HIV Infections; Humans; In Vitro Techniques; Maraviroc; Mice; Raltegravir Potassium; Tenofovir	2019
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients. Cytokine, 2020, Volume: 126 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytokines; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Inflammation; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium	2020
Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay. Journal of acquired immune deficiency syndromes (1999), 2020, 04-15, Volume: 83, Issue:5 Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biopsy; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Darunavir; Female; Gastrointestinal Tract; HIV Infections; HIV-1; Humans; Ileum; Lymph Nodes; Male; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; San Francisco; Virus Replication	2020
Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil. International journal of STD & AIDS, 2020, Volume: 31, Issue:9 Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Brazil; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Treatment Outcome; Viral Load	2020
Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV. HIV research & clinical practice, 2020, Volume: 21, Issue:4 Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Italy; Male; Middle Aged; Muscles; Raltegravir Potassium; Retrospective Studies; Viral Load	2020
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study. Medicine, 2021, Jul-30, Volume: 100, Issue:30 Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir	2021
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States	2022